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Magnesium, zinc and iron serum levels  
as potential parameters significant for  
effective glycemic control in children  
with type 1 diabetes
ABSTRACT 
Background. Various trace elements contribute to the 
development of diabetes and its complications through 
their roles in glucose metabolism and the oxidative 
stress response. The aim of this study was to ascertain 
the difference in serum magnesium, zinc and iron 
concentrations between healthy children and children 
with type 1 diabetes mellitus (T1DM). This study also 
aimed to determine whether serum concentrations 
of magnesium, zinc, and iron in children with T1DM 
correlated with the duration of the disease and the 
quality of glycemic control in this group. 
Material and methods. A total of 99 children with T1DM 
and 40 healthy children were included in this study. 
Magnesium, zinc and iron serum levels were assessed 
using the photometric method.  
Results. Significantly lower levels of magnesium and 
zinc (P < 0.001) were observed, between the T1DM 
group and the healthy control group but no statisti-
cally significant differences were found in iron levels 
(P = 0.13) between the two groups. While there were 
no statistically significant differences in serum con-
centrations with respect to the duration of disease, 
it was, however, discovered that children with poorer 
glycemic control had significantly lower serum zinc 
concentrations (P < 0.001) while magnesium and iron 
levels remained similar (P = 0.07 and 0.21 respectively). 
Conclusion. This study found that while there was no 
significant difference in iron serum levels in children with 
T1DM compared to healthy controls, children with T1DM 
did have more significantly decreased magnesium and 
zinc serum levels than the control group. Serum zinc lev-
els in this study also directly correlated to poorer glycemic 
control. Further studies are required to explore whether 
magnesium and zinc supplementation, or nutritional in-
take, could potentially be used to achieve better glycemic 
control in children with T1DM. (Clin Diabetol 2020; 9)
Key words: iron, magnesium, zinc, diabetes mellitus, 
type 1, child, supplements 
Introduction
Despite continuous efforts and rapid technologi-
cal as well as pharmaceutical advances, diabetes mel-
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litus continues to be one of the most common health 
problems in the general population. Children with 
type 1 diabetes mellitus (T1DM) are especially interest-
ing patient group, because any findings concerning 
the mechanisms of diabetes and the development of 
diabetic complications in these children can be used 
to improve their future quality of life. In view of that, 
recent studies have explored the effect of various ele-
ments in the formation of oxygen-free radicals as well 
as the effect of the ensuing oxidative stress on the 
development of diabetic complications [1, 2]. 
Magnesium is involved in the synthesis of glu-
tathione, a major antioxidant, through ensuring the 
proper functioning of the enzyme gamma glutamyl 
transpeptidase (GGT) [3]. It also plays a vital role 
in glucose metabolism, and its deficiency has been 
most commonly associated with diabetes mellitus [4] 
through its effect on the development of dyslipidaemia, 
increased insulin resistance and carbohydrate intoler-
ance [5]. Hypomagnesemia also increases the possibility 
of developing diabetic complications, particularly athe-
rosclerosis [6], diabetic retinopathy [7] and end-stage 
renal disease (ESRD) [8]. Another important element 
in glucose metabolism is zinc (Zn), which plays a role 
in secretion of insulin from pancreatic cells [9] where 
they form a Zn-insulin complex [2]. It further increases 
hepatic binding of insulin, as well as having a role in 
the modulation of insulin actions. As an antioxidant, 
zinc stabilizes membranes and reduces hydroxyl radicals 
(OH) through the induction of metallothionein synthesis 
[10]. Both of these functions are diminished in cases of 
zinc deficiency, which has impacts on glycaemic con-
trol. In children with T1DM, it has been observed that 
Zn deficiency directly correlates with poorer glycemic 
control and increased HbA1c [11]. 
In regards to serum iron levels, iron deficiency has 
been correlated with an increased HbA1c [12] in older 
patients with T1DM, although the same correlation was 
not noted in most children with diabetes [13]. Children 
with newly discovered T1DM, however, were found 
to have lower serum levels of iron than children who 
have had T1DM for a number of years [14]. Therefore, 
both increased and decreased serum levels of iron 
may have possible negative outcomes in patients with 
T1DM. On one hand, iron deficiency causes microcytic 
anemia, which is common in patients with T1DM and 
is associated with the progression of diabetes, as well 
as the development of its co-morbidities such as mi-
cro- and macroangiopathies [15]. On the other hand, 
through the Fenton reaction, increased serum levels of 
iron can generate reactive oxygen species, damaging 
tissues or cells [16]. 
Since various elements are closely linked to the 
progression of diabetes and its co-morbidities, the aim 
of this study was to ascertain the difference in serum 
magnesium, zinc and iron concentrations between 
healthy children and children with T1DM. This study 
also aimed to determine whether serum concentrations 
of magnesium, zinc, and iron in children with T1DM 
correlated with the duration of disease and the quality 
of glycemic control in this group. 
By fulfilling these aims, this study could help in-
crease understanding about the mechanisms of mag-
nesium, zinc and iron involvement in T1DM, as well 
the possibilities of supplementing those elements to 
ensure better glycemic control in children with T1DM.
Material and methods
Subjects
In this case-control study, a total of 139 children 
under 18 years of age were included, among which 
99 children had previously diagnosed T1DM, while 40 
represented a healthy control group. The control group 
was comprised of children who had undergone a stan-
dard systematic examination in a paediatric practice, 
and were not suffering from diabetes mellitus, acute 
infections, malignant, autoimmune or chronic diseases. 
For the purpose of this study the following tests were 
performed to rule out underlying diseases in the control 
group: DM was excluded in the control group based on 
blood glucose measurements (fasting plasma glucose 
< 5.6 mmol/l) and the absence of DM symptoms [17]. 
Acute infections were excluded by complete physical 
examination and normal laboratory values of white 
blood cells (WBC) and C-reactive protein (CRP). The 
T1DM group consisted of children that satisfied the 
criteria defined by the International Society for Paedia-
tric and Adolescent Diabetes (ISPAD) Clinical Practice 
Consensus Guidelines 2018 Compendium [18]. Blood 
glucose levels, levels of islet cell autoantibodies (ICA), 
glutamic acid decarboxylase 65 (GAD-65) autoanti-
bodies, and insulinoma-associated protein-2 (IA-2), as 
well as the presence of usual symptoms accompanying 
T1DM were used to determine the diagnosis of T1DM. 
Children with T1DM who were suffering from associa-
ted autoimmune diseases (such as celiac disease or 
Hashimoto thyroiditis) were not included in this study. 
In children with T1DM, serum levels of magnesium, 
zinc and iron were compared and correlated with the 
duration of disease and the quality of disease control. 
Regarding T1DM duration, children were grouped as 
either duration of T1DM under or over 1 year [17]. 
Furthermore, in accordance with the criteria defined 
by ISPAD [18], in children with long lasting disease 
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(> 1 year), glycemic control was defined as either good 
(HbA1c ≤ 7%) or poor glycemic control (HbA1c > 7%). 
Methods
Blood samples were collected in two tubes. Clot 
activator tubes (Becton, Dickinson, and Company, 
Franklin Lakes, NJ, USA) were used for glucose, as 
well as for serum zinc, iron and magnesium levels. 
The coefficients of variation (CV %) for these elements 
were as follows: for Zn within-run (1.7), between-run 
(2.1) and reference values (10.7–18.4 μmol/l); for Mg 
within-run (1.02), between-run (1.15) and reference 
values (0.74–0.97 mmol/l); for Fe within-run (1.02), 
between-run (2.09) and reference values (6–31 μmol/l). 
Samples were centrifuged for 10 minutes at 1500 g. 
K2EDTA tubes (Becton, Dickinson, and Company, 
Franklin Lakes, NJ, USA) were used for WBC count and 
haemoglobin A1c (HbA1c) measurement. Blood samples 
were collected in the fasting state according to the 
recommendations of the Clinical Laboratory Standard 
Institute (CLSI) between 7:00 and 9:00 a.m. [19]. All 
tests were performed immediately. CRP was measured 
by immunoturbidimetric assay (Roche Diagnostics 
GmbH, Mannheim, Germany), glucose was measured 
by the enzymatic method (Beckman Coulter Inc., Brea, 
USA), and zinc, magnesium as well as iron serum levels 
were measured with the photometric method using 
Beckman Coulter AU680 analyser (Beckman Coulter 
Inc., Brea, USA). WBC count was determined using a 
Sys-mex SF-3000 automated haematology analyser 
(Sysmex Corporation, Kobe, Japan) while HbA1c was 
determined by the immunoturbidimetric method on a 
Dimension EXL with an LM analyser (Siemens Health-
care Diagnostics Inc., USA).
Statistical analysis
Data were reported using descriptive statistical 
methods. The Mann–Whitney U test was used to com-
pare the medians between the two groups. All P values 
are two-sided. The level of significance is set at alpha = 
0.05. Statistical analysis was performed by the statistical 
program MedCalc Statistical Software version 19.0.5 
(MedCalc Software bvba, Ostend, Belgium; https://
www.medcalc.org; 2019).
Ethical statement
Informed consent was obtained from parents or 
legal guardians of all children enrolled in the study. The 
study was performed in accordance with the Declara-
tion of Helsinki and was approved by the Ethics Com-
mittee of Osijek University Hospital and the Faculty of 
Medicine, University of Osijek (12 March, 2018, IRB 
number: 2158-61-07-18-14).
Results
This case control study included 139 children, of which 
99 (71.2%) were diagnosed with T1DM and 40 (29.5%) 
who were used as a healthy control group after ruling 
out T1DM, acute infections or other underlying diseases. 
There were 74 girls (53.2%) and 65 boys (46.8%) with no 
significant difference between the groups (Table 1). 
The mean age of children in the two groups was 
14 years (Table 2). Table 2 further describes the char-
acteristics of the study groups (age, BMI and HbA1c). 
In children with T1DM, the median (interquartile 
range) of disease duration was 4.1 (3.9–4.3) years. 
Out of the total number (N = 99) of children with 
T1DM, 10 (9.9%) children were treated with an insulin 
pump, while the other 89 (90.1%) children used in-
tensive insulin therapy. In comparing the two groups, 
it was shown that the T1DM group had significantly 
lower levels of both magnesium (P < 0.001), and zinc 
(P < 0.001) than the control group. However, there 
was no significant difference in measured serum iron 
levels between the two groups (Table 3).
With respect to the duration of disease within the 
T1DM group, there were no significant differences in 
serum magnesium, zinc and iron levels (Table 4).
Significantly lower zinc serum levels were measured 
in children with poorer glycemic control (P < 0.001). 
However, no statistically significant difference was 
observed in serum iron and magnesium levels (Table 5).
Table 1. Distribution of respondents by gender in studied 
groups (N = 139)
Gender N (%) Total P-value†
Control  
group
T1DM*  
group
Boys 18 (45.0) 47 (47.5) 65 (46.8) 0.85
Girls 22 (55.0) 52 (52.5) 74 (53.2)
Total 40 (100) 99 (100) 139 (100)
*T1DM group — children with type 1 diabetes mellitus; †Fisher exact test
Table 2. Demographic and clinical characteristics of study 
groups (N = 136) 
Factor Median (interquartile range) P-value†
Control  
group
T1DM*  
group
Age (years) .013 (13.0–17.0) .0012 (8.0–14.0) 0.09
BMI [kg/m2] 16.9 (15.1–18.1) 17.1 (14.9–21.3) 0.11
HbA1c (%) 05.1 (4.7–5.5) 0.7.9 (7.2–8.6)0 0.03
BMI — body mass index; HbA1c — haemoglobin A1c; *T1DM group — 
children with type 1 diabetes mellitus; †Mann–Whitney U test
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Discussion
In recent times, T1DM in paediatric patients has 
become one of the most researched endocrinological 
disorders in the world. Among the many things stu-
died, the correlation between the imbalance of trace 
elements in the human body and their effects on the 
severity of T1DM through the effects of oxidative stress 
is particularly interesting [2]. It has been suggested that 
achieving the balance of various trace elements in the 
body could improve glycemic control in T1DM patients 
by using relatively simple means of pharmaceutical and 
nutritional correction. Magnesium and zinc are the 
obvious potential candidates due to their important 
roles in glucose metabolism and antioxidant response. 
The results of this study demonstrate significantly 
lower serum levels of magnesium and zinc in children 
with T1DM when compared to healthy controls. These 
results are in accordance with other similar studies [2, 
20, 21]. Decreased magnesium serum levels in children 
with T1DM were reported in the study by Lin et al. [11] 
but, without the similar decrease of serum zinc levels 
when compared with healthy controls. Similar serum 
zinc levels between T1DM and healthy group were also 
reported in other studies [22, 23].
Zn plays a major role in the stabilisation of insulin 
hexamers and the pancreatic storage of the hormone, 
and is an efficient antioxidant. Zn may also have an 
indirect insulin-like effect, with genetic studies identify-
ing the islet-restricted Zn transporter ZnT8 as a likely 
player in the control of insulin secretion. When the 
serum Zn concentration falls, there is a concomitant 
reduction in insulin secretion and peripheral insulin 
sensitivity [24]. Ahmed and Helal [20] in their study 
comprised of 25 children with T1DM and 13 apparently 
healthy controls, reported decreased magnesium and 
zinc serum levels in T1DM children compared to the 
healthy controls. These results could be explained by 
the fact that magnesium and zinc levels may decrease 
due to urinary loss by osmotic action, glucosuria and 
hyperglycemia [20]. 
With respect to the duration of the disease within 
the T1DM group, there were no significant differences 
Table 3. Differences in serum magnesium, zinc and iron levels in studied groups (N = 139)  
Elements Median (interquartile range) HL diff. 95% CI P-value
Control T1DM
Magnesium [mg] 0.87 (0.83–0.90) 0.80 (0.75–0,84) –0.08 –0.1 to –0.05 < 0.001*
Zinc [mmol/L] 12.9 (11.8–13.8) 10.7 (9.3–12.1) –2.1 –2.7 to –1.4 < 0.001*
Iron [μmol/L] 15.9 (10.6–20.5) 14.4 (9.7–18.03) –1.7 –4.1 to 0.6 0.13
HL diff. — Hodges–Lehmann median difference; *significant at P ≤ 0.05
Table 4. Comparison of serum magnesium, zinc and iron levels in children with T1DM (N = 99) in regard to the duration 
of T1DM
Elements Median (interquartile range) HL diff. 95% CI P-value
Under 1 year (n = 7) Over 1 year (n = 92)
Magnesium [mg] 0.75 (0.72–0.79) 0.70 (0.75–0.84) 0.04 –0.02 to 0.09 0.12
Zinc [mmol/L] 10.7 (10.2–11.1) 10.7 (9.2–12.1) –0.3 –1.6 to 1.2 0.73
Iron [μmol L] 15.4 (12.4–17.8) 13.9 (9.7–18.1) –1.5 –5.5 to 2.6 0.45
HL diff. — Hodges–Lehmann median difference
Table 5. Comparison of serum magnesium, zinc and iron levels in children with T1DM (> 1 year) according to the quality 
of glycemic control in (N = 92) 
Elements Median (interquartile range) HL diff. 95% CI P-value
HbA1c ≤ 7% (n = 48) HbA1c > 7% (n = 44)
Magnesium [mg] 0.82 (0.76–0.85) 0.79 (0.75–0.82) –0.02 –0.04 to 0.01 0.21
Zinc [mmol/L] 11.2 (10.2–13.1) 9.9 (8.8–11.2) –1.4 –2.2 to –0.6 < 0.001*
Iron [μmol/L] 15.2 (10.9–18.8) 11.5 (9.6–16.5) –2.3 –4.7 to 0.10 0.07
HL diff. — Hodges–Lehmann median difference; *significant at P ≤ 0.05
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found in this study in serum magnesium, zinc and iron 
levels. This finding was similar to the study by Estakhri 
et al. in which zinc serum levels did not correlate to the 
duration of disease [23]. However, Ahmed and Helal 
[20] in their study report a negative correlation of serum 
magnesium and zinc levels with the duration of T1DM. 
Possible reasons for these contradictory results can be 
due to the difference in duration of disease between pa-
tient populations, quality of glycemic control, genetic, 
dietary characteristics, and environmental factors [23].
Significantly, in this study, lower zinc serum levels 
were observed in children with poorer glycemic control. 
Similarly, decreased levels of serum zinc in children with 
T1DM and poorer glycemic control were also described 
in the studies of Alghobashy et al. from 2018 [1] and Lin 
et al. from 2014 [11]. The negative correlation of serum 
zinc level with the degree of disease control was also 
observed by Ahmed and Helal [20], however, the study 
by Estakhri et al. [23] showed that the level of serum 
zinc was not influenced by the quality of the glycemic 
control. Although, this discrepancy may be explained 
by the fact that the study of Estakhri et al. [23] included 
a significantly smaller number of children with T1DM 
(N = 30) whose disease duration was significantly 
shorter (2.5 years). Lower levels of zinc increase the 
production of hydroxyl radicals, facilitating oxidative 
stress in children with T1DM, through the decrease of 
iron binding to the cell membrane as well as through 
the inhibition of metallothionens [11]. The negative 
correlation of zinc levels with HbA1c levels in children 
with poorer glycaemic control is one observable nega-
tive effect of this oxidative injury [2]. Decreased zinc 
serum levels are also associated with impaired utilisa-
tion of glucose and decreased insulin sensitivity [25]. 
The aforementioned negative correlation of serum 
Zn levels with respect to HbA1c level can be explained 
by increased urinary micronutrient loss due to increased 
osmotic diuresis caused by hyperglycemia [1]. The 
absence of a correlation between disease duration 
and serum HbA1c level is most likely the result of good 
glycemic control and relatively short average disease 
duration in our study group of children with T1DM (4.1 
years). In contrast, the study results of Al Ghobashy et 
al. [1] indicate a positive correlation of disease duration 
with HbA1c levels in children with T1DM. However, the 
children with T1DM in this study had a mean age of 
illness of 4.8 years, with 75% of them defined as having 
poorly controlled disease. 
Zinc supplementations can, through the increase 
of serum zinc levels, help to decrease diabetes-induced 
oxidative stress [2]. The fact that zinc levels in this 
study directly correlated to poorer glycemic control, 
represented by higher HbA1c, seems to further suggest 
that zinc correction could be beneficial to children 
with T1DM. 
Indeed, several studies, such as Jayarwardena et 
al. [25] and the meta-analysis by Capdor et al. [26] 
indicated that the use of zinc supplementation showed 
a tendency to decrease HbA1c levels in patients with 
T1DM. Magnesium supplements were administered 
to children with T1DM during 3 months in the study 
conducted by Shahbah et al. [27] and were shown to 
significantly decrease HbA1c levels. Introducing more 
magnesium and zinc rich food in the diet of children 
with T1DM probably represents an easy and beneficial 
method to balance the element’s serum levels and 
improve glycemic control.
While iron supplementation can certainly alleviate 
the iron deficiency anemia associated with diabetes [14] 
as well as its possible negative effects on non-verbal 
intelligence as observed by Mojs et al. [28], there is 
currently not enough clinical evidence on their use in 
children with T1DM. 
Limitations of this study include its cross-sectional 
design, as well as the fact that data were collected from 
a single centre and therefore may not be extrapolate 
to other population groups. 
In conclusion, magnesium and zinc supplementa-
tion or nutritional intake could potentially be included 
in the standard treatment of children with T1DM to 
achieve better glycemic control, however, further 
multi-centre, longituidal studies are required. Further-
more, the usage of iron supplementation in diabetic 
children is currently controversial and also requires 
further research. 
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